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Abstract
Cutaneous T-cell lymphomas (CTCL) comprise a group of diseases characterized by the accumulation of malignant T cells within the
skin. Sezary syndrome represents an aggressive form of CTCL, in which the skin is diffusely affected and the peripheral blood is
involved. It is characterized by the triad of generalized erythroderma, lymphadenopathy, and neoplastic T cells (Sezary cells) in the
skin, lymph nodes, and peripheral blood. Leonine facies is rare and corresponds to the morphologic manifestation of diffuse dermal
infiltration of the face. It can occur in cutaneous T-cell lymphomas that progress during years without therapy. We present the case of
a 54-year-old man with Sezary syndrome presenting with leonine facies, unresponsive to conventional therapies; he exhibited a
promising response to subcutaneous low-dose alemtuzumab.
A 54-year-old male was observed in our department because of a four-year history of generalized pruritus and cutaneous lesions on
the face. On physical examination he showed generalized erythroderma, lichenification, diffuse alopecia, madarosis, and diffuse
infiltration of facial skin, particularly on the eyebrows and ears, giving the appearance of a leonine facies (Figures 1a and 1b). Small
(<1 cm) axillary, supraclavicular, and inguinal lymph nodes were palpable. His physical examination was otherwise normal. His past
medical history was irrelevant and he was not taking any prescribed or over-the-counter medications.
Figure 1 Figure 2
Figure 1a. Diffuse alopecia, madarosis and diffuse infiltration of facial skin
giving the appearance of leonine facies
Figure 1b. Infiltration of the ear
Figure 1c. Third week of alemtuzumab: marked reduction of the facial
infiltration
Figure 2a. Infiltration of the dermis by atypical lymphocytic cells. No
epidermotropism (H&E, x4)
Figure 2b. Positivity for CD3 (x4)
Figure 2c. Positivity for CD4 (x10)
Figure 2d. Negativity for CD8 (x4)
A skin biopsy was made revealing an atrophic epidermis with follicular dilation and hyperkeratosis. The dermis was diffusely infiltrated
with atypical lymphocytic cells, consisting of large cells with hyperchromatic and cerebriform nuclei (Figure 2a). There was no
epidermotropism. The lymphoid infiltrate was characterized immunohistochemically by positivity for CD3 (Figure 2b) and CD4 (Figure
2c) and negativity for CD8 (Figure 2d). Flow cytometry showed a mixture of small and large CD4+ lymphocytic T-cells, with an
aberrant CD3/TCRαβ+low, CD2+low, CD7- immunophenotype. Molecular biology studies revealed a monoclonal TCR γ-gene
rearrangement.
The full blood count revealed 18.59x109/L leukocytes, 7.81 x109/L neutrophils, 1.39 x109/L lymphocytes, hemoglobin 15.2 g/dL, and
platelets 395 x109/L, with 45.5 percent of atypical lymphocytes. Biochemistry studies were relevant for high LDH (430 UI/L) and high
β2-microglobulin (2341 ng/mL) levels. Thoracic, abdominal and pelvic CT scans were unremarkable and the bone marrow biopsy
revealed invasion of atypical lymphocytic cells. Flow cytometry and molecular biology studies confirmed the presence of the
phenotypically abnormal monoclonal CD4+ T cells in the peripheral blood and bone marrow. The diagnosis of Sezary syndrome (SS)
(T4NxM0B2) was made.
The patient started combined systemic chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
accomplishing four cycles with no response. A regimen of low dose subcutaneous (sc) alemtuzumab was then introduced, beginning
with 3 mg in the first day, followed by 10 mg three times a week for twelve weeks. There was a transient interruption of the treatment
at the fourth week, with a duration of six weeks, for asymptomatic reactivation of cytomegalovirus. We observed a marked reduction of
the erythema and of the facial infiltration beginning in the third week (Figure 1c). Sezary cells reached an absolute count of zero by the
second week of treatment; by this time that the patient noted almost no pruritus. Currently, three months after the end of the
treatment, there is a slight worsening of clinical and laboratory parameters.
Leonine facies is rare and corresponds to the morphologic manifestation of diffuse dermal infiltration of the face. It can occur in a
variety of conditions [1], although it is more frequent in association with lepromatous leprosy and cutaneous T-cell lymphomas. Most
of the time it occurs as the diseases progress without therapy.
Sezary syndrome is a rare disease, corresponding to 5 percent of all primary cutaneous T cell lymphomas [2]. Classically, it is
characterized by the triad of erythroderma, generalized lymphadenopathy, and neoplastic T cells (Sezary cells) in the skin, lymph
nodes, and peripheral blood [3]. Besides the erythroderma, it presents with generalized exfoliation, palmoplantar keratoderma,
alopecia, and onychodystrophy [3].
The histological features in SS may be similar to those in mycosis fungoides, although in SS the cellular infiltrates are more often
monotonous and epidermotropism may sometimes be absent. Usually, the neoplastic T cells have a CD3+, CD4+ and CD8−
phenotype [1].
In 2002, the International Society of Cutaneous Lymphoma proposed new criteria for SS diagnosis, including one or more of the
following parameters: an absolute Sezary cell count of least 1000 cells/mm³; demonstration of immunophenotypic abnormalities (an
expanded CD4 T-cell population resulting in a CD4/CD8 ratio more than 10; loss of any or all of the T-cell antigens CD2, CD3, CD4,
and CD5); or the demonstration of a T-cell clone in the peripheral blood by molecular or cytogenetic methods [2].
The prognosis is in general poor and the median survival rate at 5 years is 24 percent [4]. Patients frequently die of opportunistic
infections related to the immunosuppression that is inherent to the therapy [3].
Conventional treatment relies on systemic combined chemotherapy, alpha interpheron, photochemotherapy, and extracorporeal
photopheresis, usually with partial, clinically unsatisfactory and transient responses [3].
Alemtuzumab is an anti-CD52 recombinant DNA-derived humanized monoclonal antibody that has been used in the last years for
treatment of chronic lymphocytic leukemia and T-cell lymphomas, including primary cutaneous T-cell lymphoma, though never as first-
line. In a study conducted in 2009 by Querfeld et al [5], 19 patients with advanced erythrodermic cutaneous T-cell lymphomas were
treated with alemtuzumab intravenously using an escalating dose regimen with a final dose of 30 mg three times a week for 4 weeks,
followed by subcutaneous administration for 8 weeks, with a response rate of 84 percent.
Bexarotene has been used in these patients, but the major complication, is the reactivation of cytomegalovirus, especially if used in
the standard dose regimen of 30 mg intravenously or subcutaneously (sc), three times a week. In 2007 Bernengo et al [6] studied the
efficacy of sc low-dose alemtuzumab (3 mg on day 1, then 10 mg on alternating days) in the treatment of fourteen SS patients. They
concluded that the alemtuzumab given sc at very low doses has a good toxicity profile, high response rate, and causes durable
remissions in SS patients with high tumor burden in the peripheral blood.
We applied this knowledge to our patient and found that by the beginning the second week there was already a significant decrease of
atypical T cells in the peripheral blood and a waning of erythema and pruritus.
With this report we intend to present a rare manifestation of cutaneous T-cell lymphoma that particularly arises in patients untreated
over years of evolution. Treatment with low-dose sc alemtuzumab seems to be useful in controlling the symptoms and progression of
SS.
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